CLINICAL TRIALS PROFILE FOR APALUTAMIDE
✉ Email this page to a colleague
All Clinical Trials for Apalutamide
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01171898 ↗ | Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC) | Active, not recruiting | Aragon Pharmaceuticals, Inc. | Phase 1/Phase 2 | 2010-07-26 | The purpose of this study is to assess the safety and activity of ARN-509 in men with advanced castration resistant prostate cancer. Patients will first be enrolled into Phase 1 of the study to identify a tolerable dose for the Phase 2 portion of the study. In the Phase 2, 3 different cohorts of patients will be enrolled to evaluate the safety and activity of ARN-509. |
| NCT01946204 ↗ | A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer | Active, not recruiting | Aragon Pharmaceuticals, Inc. | Phase 3 | 2013-10-14 | The purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men with high-risk non-metastatic castration-resistant prostate cancer. |
| NCT02106507 ↗ | ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate | Completed | Aragon Pharmaceuticals, Inc. | Phase 1 | 2014-04-01 | The purpose of this study is to test the safety of the combination of apalutamide plus everolimus at different dose levels. |
| NCT02106507 ↗ | ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate | Completed | Memorial Sloan Kettering Cancer Center | Phase 1 | 2014-04-01 | The purpose of this study is to test the safety of the combination of apalutamide plus everolimus at different dose levels. |
| NCT02257736 ↗ | An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRP | Active, not recruiting | Aragon Pharmaceuticals, Inc. | Phase 3 | 2014-11-26 | The purpose of this study is to compare the radiographic progression-free survival (rPFS) of apalutamide in combination with abiraterone acetate (AA) plus prednisone or prednisolone (AAP) and AAP in participants with chemotherapy-naive (participants who did not receive any chemotherapy [treatment of cancer using drugs]) metastatic castration-resistant prostate cancer (mCRPC) (cancer of prostate gland [gland that makes fluid that aids movement of sperm]). |
| NCT02366494 ↗ | Micro RNAs to Predict Response to Androgen Deprivation Therapy | Active, not recruiting | Medical College of Wisconsin | 2015-04-29 | Identify exosomal micro RNA that predict responses to ADT | |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Apalutamide
Condition Name
Clinical Trial Locations for Apalutamide
Trials by Country
Clinical Trial Progress for Apalutamide
Clinical Trial Phase
Clinical Trial Sponsors for Apalutamide
Sponsor Name
